Effect of monosialotetrahexosylganglioside sodium combined with cerebroprotein hydrolysate on serum indexes and immune response in patients with Parkinson's disease
Objective: To study the effect of monosialotetrahexosylganglioside sodium combined with cerebroprotein hydrolysate on serum indexes and immune response in patients with Parkinson's disease. Methods: A total of 94 patients with Parkinson's disease diagnosed and treated in our hospital be...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2016-11-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/201622/9.pdf |
Summary: | Objective: To study the effect of monosialotetrahexosylganglioside sodium combined
with cerebroprotein hydrolysate on serum indexes and immune response in patients with
Parkinson's disease. Methods: A total of 94 patients with Parkinson's disease diagnosed and
treated in our hospital between March 2012 and December 2014 were selected and randomly
divided into observation who received monosialotetrahexosylganglioside sodium combined
with cerebroprotein hydrolysate treatment group and control group who received monosialot
etrahexosylganglioside sodium monotherapy, and the levels of CD4+
T lymphocyte subsets in
peripheral blood as well as the levels of cytokines and nerve injury molecules in serum were
determined. Results: CD4+
CD45RA+
naive T cell and CD4+
CD25highFoxp3+
regulatory T
cell levels in peripheral blood of observation group were significantly higher than those of
control group while CD4+
CD45RO+
memory T cell level in peripheral blood was significantly
lower than that of control group; serum IFN-γ, TNF-α and IL-17 as well as NSE and S100
β levels were significantly lower than those of control group while serum IL-4 and IL-10
as well as Aβ1-42 and BDNF levels were significantly higher than those of control group.
Conclusions: Monosialotetrahexosylganglioside sodium combined with cerebroprotein
hydrolysate treatment of PD can adjust the immune function and reduce the inflammatory
injury and immune injury of the neurons. |
---|---|
ISSN: | 1007-1237 1007-1237 |